Antibiotics Simplified 5th Edition by Jason C. Gallagher, ISBN-13: 978-1284250060

Description

Antibiotics Simplified 5th Edition by Jason C. Gallagher, ISBN-13: 978-1284250060

[PDF eBook eTextbook]

• Publisher: ‎ Jones & Bartlett Learning; 5th edition (July 25, 2022)
• Language: ‎ English
• 352 pages
• ISBN-10: ‎ 1284250067
• ISBN-13: ‎ 978-1284250060

“This book focuses on key points of basic microbiology and antimicrobial pharmacotherapy and organizes them into a concise guide … must-have antimicrobial reference guide for all medical and pharmacy students.” – Lindsay McDonnell, PharmD for Doody’s Review Service

Antibiotics Simplified, Fifth Edition is a best-selling, succinct guide designed to bridge knowledge gained in basic sciences courses with clinical practice in infectious diseases. This practical text reviews basic microbiology and how to approach the pharmacotherapy of a patient with a presumed infection. It also contains concise Drug Class Reviews with an explanation of the characteristics of various classes of antibacterial drugs and antifungal drugs. This text simplifies learning infectious disease pharmacotherapy and condenses the many facts that are taught about antibiotics into one quick reference guide. This guide will help students learn the characteristics of antibiotics and why an antibiotic is useful for an indication. With an understanding of the characteristics of the antibiotics, students will be able to make a logical choice to treat an infection more easily.

Table of Contents:

Acknowledgments

Introduction

New to the Fifth Edition

PART 1: Considerations with Antibiotic Therapy

Chapter 1: The Wonderful World of Microbiology

Chapter 2: General Approach to Infectious Diseases

Chapter 3: Antibiotic Pharmacokinetics

Chapter 4: Antibiotic Pharmacodynamics

Chapter 5: Adverse Consequences of Antibiotic Use

Chapter 6: Antibiotic Resistance

PART 2: Antibacterial Drugs

Chapter 7: Beta-Lactams

Penicillins

Natural Penicillins

Antistaphylococcal Penicillins

Aminopenicillins

Penicillin/Beta-lactamase Inhibitor Combinations

Cephalosporins

First-generation Cephalosporins

Second-generation Cephalosporins

Third-generation Cephalosporins

Fourth-generation Cephalosporins

Anti-MRSA Cephalosporins

Siderophore Cephalosporin

Cephalosporin/Beta-lactamase Inhibitor Combinations

Carbapenems

Carbapenem/Beta-lactamase Inhibitor Combinations

Monobactams

Chapter 8: Glycopeptides and Short-Acting Lipoglycopeptides

Chapter 9: Long-Acting Glycopeptides

Chapter 10: Fluoroquinolones

Chapter 11: Aminoglycosides

Chapter 12: Tetracyclines and Modified Tetracyclines

Chapter 13: Macrolides

Chapter 14: Oxazolidinones

Chapter 15: Nitroimidazoles

Chapter 16: Nitrofurans and Fosfomycin

Chapter 17: Streptogramins

Chapter 18: Cyclic Lipopeptides

Chapter 19: Folate Antagonists

Chapter 20: Lincosamides

Chapter 21: Polymyxins

Chapter 22: Clostridioides difficile-Specific Agents

PART 3: Antimycobacterial Drugs

Chapter 23: Antimycobacterial Drugs

Chapter 24: Rifamycins

Chapter 25: Isoniazid

Chapter 26: Pyrazinamide

Chapter 27: Ethambutol

PART 4: Antifungal Drugs

Chapter 28: Antifungal Drugs

Chapter 29: Polyenes

Chapter 30: Antifungal Antimetabolite

Chapter 31: Azoles

Fluconazole

Itraconazole

Voriconazole

Posaconazole

Isavuconazole

Chapter 32: Echinocandins

Chapter 33: Terpenoids

PART 5: Antiviral Drugs

Chapter 34: Antiviral Drugs

Chapter 35: Anti-Herpes Simplex Virus and Varicella-Zoster Virus Agents

Chapter 36: Anti-cytomegalovirus Agents

Chapter 37: Anti-influenza Antivirals

Chapter 38: Anti-coronavirus Antivirals

Chapter 39: Antiretroviral Drugs

Nucleoside and Nucleotide Reverse Transcriptase Inhibitors

Non-nucleoside Reverse Transcriptase Inhibitors

Protease Inhibitors

Integrase Inhibitors

Entry, Attachment, and Fusion Inhibitors

Chapter 40: Antiviral Interferons

Chapter 41: Direct-Acting Anti-hepatitis C Agents

Chapter 42: Ribavirin

Chapter 43: Hepatitis B Nucleoside Analogs

Chapter 44: Anti-SARS-CoV-2 Antibody Therapies

PART 6: Antiparasitic Drugs

Chapter 45: Antiparasitic Drugs

Chapter 46: Quinolines

Chapter 47: Atovaquone

Chapter 48: Benzimidazoles

Chapter 49: Pentamidine

Chapter 50: Ivermectin

Chapter 51: Artemisinins

Appendix 1: Selected Normal Human Flora

Appendix 2: Spectrum of Activity

Appendix 3: Empiric Regimens for Common Infections

Index

Jason C. Gallagher is an Associate Professor in the Department of Pharmacy Practice at Temple University, and a Clinical Pharmacy Specialist in Infectious Diseases at Temple University Hospital (TUH). His clinical service is with the Infectious Diseases Consult team at TUH where he also serves on committees related to antibiotic use and guideline preparation. He lectures on the pharmacotherapy of infectious diseases and the practice of clinical pharmacy at Temple and also teaches antibiotic pharmacology at Drexel University School of Medicine, where he has an adjunct appointment. Dr. Gallagher’s research interests focus on the treatment of resistant Gram-negative and Gram-positive infections and on antifungal pharmacotherapy. He is a past-president of the Mid-Atlantic College of Clinical Pharmacy.

Conan MacDougall is an Assistant Professor of Clinical Pharmacy in the Department of Clinical Pharmacy at the University of California, San Francisco. He provides clinical service to the Infectious Diseases Consult Service at UCSF Medical Center and participates in UCSF’s antimicrobial management program. His research interests include the pharmacoepidemiology of antimicrobial use in hospitals and communities, associations between antimicrobial use and resistance, and the clinical use of antifungal agents. Dr. MacDougall co-coordinates the clinical pharmacy therapeutics course in infectious diseases and oncology, precepts students on the infectious diseases rotation, and lectures on antimicrobial agent pharmacology.

What makes us different?

• Instant Download

• Always Competitive Pricing

• 100% Privacy

• FREE Sample Available

• 24-7 LIVE Customer Support